IMMX: Immix Net earnings per share (EPS TTM)

Immix Biopharma (IMMX) - corporate logo

Immix Biopharma, Inc. (IMMX) operates as a flexible scientific hub, outsourcing production and testing to external partners. The current EPS TTM historical trend on the GURU.Markets chart shows that the current value is -0.83. A critical dependence on third-party contractors and the early stages of cancer therapy development create negative operating leverage, increasing per-unit R&D costs.

IMMX Immix Biopharma, Inc. Net earnings per share for the last 12 months (07/04/2022 - 11/15/2026)

Summary analytical data breakdowns for Immix Biopharma, Inc. (IMMX)

- share price and expert price forecast:
Fundamental valuation:IMMX - immixbio.com
Flagship merchandise of Immix

Net income per share measures the owner's stake in the final annual financial result. By analyzing this annual net income per share chart, an investor assesses the efficiency of capital generation relative to the total shares outstanding. The metric is calculated by dividing the total income over 12 months by the total number of shares. For Immix Biopharma, Inc. (IMMX), negative values reflect the costs of the large-scale deployment of CAR-T therapy clinical trials. This confirms a stage of active investment in cell modification to secure future approvals.

Main competitors

IBRX: Net earnings per share for the last 12 months|Earnings per share for the trailing year IMCR (Immunocore)|JANX: Net earnings per share (EPS TTM)|RCUS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months zymeworks.com|Net earnings per share for the last 12 months tangotx.com (TNGX)|Earnings per share for the last twelve months Iovance Biotherapeutics Inc (IOVA)|Net earnings per share for the last 12 months Immatics Corp IMTX|Xencor Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Compass Therapeutics Corp CMPX|REPL - Earnings per share for the last twelve months|LYEL (lyell.com) - Earnings per share for the last 12 months|Innate Pharma S.A (IPHA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Pyxis Oncology, Inc. (PYXS)|Net earnings per share for the last 12 months CGEN|IOBT - Net earnings per share for the trailing year|Net earnings per share for the last 12 months STRO (Sutro Bio)|Earnings per share for the last four quarters INKT|Net earnings per share (EPS TTM) HOWL (Werewolf Therapeutics)|Earnings per share for the trailing year ALXO|CUE - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months PDS Biotechnology Corporation|Sonnet BioTherapeutics Holdings Inc. (SONN) - Earnings per share for the last twelve months|MAIA Biotechnology - Earnings per share for the trailing year|LIMN (liminatuspharma.com) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) lavatherapeutics.com|Earnings per share for the last twelve months NextCure (NXTC)|LPTX: Earnings per one share for the last 12 months|Intensity Therapeutics, Inc. - Net earnings per share for the last 12 months|Sensei Biotherapeutics (SNSE) - Net earnings per one share for the last twelve months|TOVX: Net earnings per share for the last 12 months|Net earnings per share for the trailing year Gritstone bio (GRTS)|KA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NexImmune, Inc. (NEXI)|Earnings per share for the last twelve months turnstonebio.com|Net earnings per share for the last 12 months Vaccinex, Inc. (VCNX)|Earnings per share for the last twelve months Harpoon Therapeutics (HARP)